Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PITRM1 antisense RNA 1 (PITRM1-AS1) is designated as a long non-coding RNA transcribed antisense to the PITRM1 (pitrilysin metallopeptidase 1) gene. There is currently no experimental data or literature supporting its function, role in disease, or its validity as a biological target. All recent research and therapeutic interest relate to the protein-coding gene PITRM1, a mitochondrial metallopeptidase involved in mitochondrial transit peptide degradation and amyloid beta processing, with documented links to neurodegenerative disease. PITRM1-AS1 itself is not addressed as a therapeutic target, nor is it described as having a clear functional role. If you require information on the protein-coding gene PITRM1, which is an established mitochondrial protease with disease links, please specify.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PITRM1 antisense RNA 1 (PITRM1-AS1).